Advertisement

U.S. regulators approve second gene therapy for blood cancer

By Associated Press  |  October 19, 2017
U.S. regulators approve second gene therapy for blood cancer

Kite Pharma's newly approved blood cancer treatment, Yescarta, uses gene therapy techniques not to fix disease-causing genes but to turbocharge T cells, immune system soldiers that cancer can often evade.

Pharmaceuticals

Anthem's new PBM to spark change throughout the industry

Anthem's new PBM to spark change throughout the industry

There has been heightened scrutiny over pharmacy benefit managers' role in drug pricing in recent years. Anthem's creation of its own pharmacy benefit management company could drive change throughout the industry as health plans and PBMs aim to maintain their competitive edge, experts said.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print